Document:

Adamis Pharmaceuticals Corporation 8-K

Exhibit
10.1 

  

PURCHASE AGREEMENT

 

THIS PURCHASE AGREEMENT
(“Agreement”) is made as of the  19th day of August, 2014, by and among Adamis Pharmaceuticals
Corporation, a Delaware corporation (the “Company”), and each entity named on the signature page of this
Agreement (each an “Investor” and collectively, the “Investors”).

 

BACKGROUND

 

A.         The Company and the
Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the
provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange Commission
(the “SEC”) under the Securities Act of 1933, as amended.

 

B.         The
Company is offering, upon the terms and conditions stated in this Agreement, up to an aggregate of (i) 1,418,439  shares
(the “Shares”) of Series A Convertible Preferred Stock, par value $0.0001 per share, convertible into a
number of shares (“Conversion Shares”) of the Company’s Common Stock, par value $0.0001 (together
with any securities into which such shares may be reclassified, the “Common Stock”), and
(ii) Warrants in the form attached hereto as Exhibit A (the “Warrants”) to purchase an
aggregate of  1,418,439 shares of Common Stock (the “Warrant Shares”) at an initial exercise price of
$3.40 per Warrant Share. As used herein, “Securities” means, collectively, the Shares, Conversion
Shares, the Warrants and the Warrant Shares.

 

C.         The
Shares and the Warrants are being offered as units (the “Units”), with each Unit consisting of (i) one
Share and (ii) one Warrant to purchase one Warrant Share, all at a per Unit price of $3.525 (the “Per Unit Purchase
Price”). The Units will not be certificated, and the Shares and the Warrants will be issued separately.

 

D.         The Investors wish to
purchase from the Company, and the Company wishes to sell and issue to the Investors the number of Units specified on the signature
page to this Agreement at the Per Unit Purchase Price.

 

E.         Contemporaneous with
the sale of the Units, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto
as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide
certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

AGREEMENT

 

In consideration of the mutual
promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:

 

1.         Definitions.
In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms
shall have the meanings set forth below:

 

    	1

    	 

    

 

“Affiliate”
means, as to any Person (the “subject Person”), any other Person (a) that directly or indirectly through one
or more intermediaries controls or is controlled by, or is under direct or indirect common control with, the subject Person, (b)
that directly or indirectly beneficially owns or holds ten percent (10%) or more of any class of voting equity of the subject Person,
or (c) ten percent (10%) or more of the voting equity of which is directly or indirectly beneficially owned or held by the subject
Person. For the purposes of this definition, “control” when used with respect to any Person means the power
to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities,
through representation on such Person’s board of directors or other management committee or group, by contract or otherwise.

 

“Business Day”
means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

 

“Certificate of Designation”
means the Certificate of Designation, substantially in the form attached hereto as Exhibit C, to be filed by the Company
with the Secretary of State of Delaware, establishing and defining the rights of the Shares.

 

“Certificates”
representing any of the Securities shall mean either (i) certificates representing such Securities or, (ii) if Securities are issued
in uncertificated form, then comparable share notices reflecting such Securities).

 

“Common Stock Equivalents”
means any securities of the Company which entitle the holder thereof to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for,
or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company’s Knowledge”
means the knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company.

 

“Confidential Information”
means trade secrets, confidential information and know-how (including, but not limited to, ideas, formulae, compositions, processes,
procedures and techniques, research and development information, computer program code, performance specifications, support documentation,
drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related information).

 

“ERISA” means
the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder.

 

“Intellectual Property”
means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or not patentable and
whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans
and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights and copyrightable
works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software (including,
but not limited to, data, data bases and documentation).

 

    	2

    	 

    

 

“Key Employee”
has the meaning set forth in Section 4.28.

 

“Material Adverse Effect”
means a material adverse effect (i) on the business, assets, liabilities, results of operations, or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or on the authority or ability of the Company to perform its obligations
under the Transaction Documents; provided, however, that for purposes of this Agreement, “Material Adverse Effect”
shall not include any effect attributable solely to the changes in the trading price of the Common Stock or (ii) on the Investor’s
rights as a holder of the Preferred Stock or under the Warrants.

 

“Material Contract”
means any contract, instrument or other agreement to which the Company or any Subsidiary is a party or by which it is bound which
is material to the business of the Company and its Subsidiaries, taken as a whole, including those such contracts, instruments
or agreements that have been filed as exhibits to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.

 

“NASDAQ CM”
has the meaning set forth in Section 4.20.

 

“Pension Plan”
means an employee benefit plan (as defined in ERISA) maintained by the Company for employees of the Company or any of its Affiliates.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Registrable Securities”
means the Conversion Shares and the Warrant Shares, any other shares of Common Stock issuable pursuant to the terms of the Certificate
of Designation or the Warrants, and any shares of capital stock issued or issuable from time to time (with any adjustments) in
replacement of, in exchange for or otherwise in respect of the Conversion Shares or the Warrant Shares; provided, however,
that “Registrable Securities” shall not include any such shares that have been sold to the public pursuant to the Registration
Statement or Rule 144 or that can be publicly sold to the public without volume restrictions pursuant to Rule 144 (and giving effect
to the ability to net exercise the Warrants pursuant to the provisions of the Warrants).

 

“Registration Statement”
has the meaning set forth in the Registration Rights Agreement.

 

“Required Investors”
means any Investor which, together with its Affiliates, beneficially owns at least a majority of the Shares then beneficially owned
by the Investors.

 

“Rule 144”
means Rule 144 under the 1933 Act, or any successor provision.

 

“SEC Filings”
has the meaning set forth in Section 4.7.

 

“Subsidiary”
means any “significant” subsidiary of the Company, as defined in Article 1-02(w) of Regulation S-X.

 

    	3

    	 

    

 

“Trading Day”
means any day on which the NYSE MKT, the NASDAQ CM, the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock
Exchange or the OTC Bulletin Board (or any successors to any of the foregoing) is open for business.

 

“Transaction Documents”
means this Agreement, the Warrants, the Registration Rights Agreement and all other agreements, documents and other instruments
executed and delivered by or on behalf of the Company or any of its officers at the Closing.

 

“VWAP” means,
for any Trading Day, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a national securities exchange or trading market (with such exchange or market including, without limitation, the
Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, The New York Stock Exchange, Inc., the NYSE or
Amex, or the OTC Bulletin Board including the OTCQX or OTCQB) (a “Trading Market”), the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock
is then listed or quoted as reported by Bloomberg L.P. (or other reliable source) based on a Trading Day from 9:30 a.m. (New York
City time) (or such other time as the Trading Market publicly announces is the official open of trading) to 4:00 p.m. (New York
City time) (or such other time as the Trading Market publicly announces is the official close of trading), (b)  if no daily
volume weighted average prices are reported by Bloomberg (or other reliable source), the average of the highest closing bid price
and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets” by
OTC Markets LLC, or (c) in all other cases, the fair market value of a share of Common Stock as mutually determined by the
Company and Investor.

 

“1933 Act”
means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

2.         Purchase and Sale
of the Units. Subject to the terms and conditions of this Agreement, on the Closing Date, each Investor shall purchase, and
the Company shall sell and issue to each Investor, the number of Units set forth opposite the Investor’s name on the signature
page attached hereto at a price per Unit equal to the Per Unit Purchase Price.

 

3.         Closing.
The purchase and sale of the Units to be purchased by the Investors hereunder shall occur on the date hereof, subject to the
satisfaction or waiver of the conditions specified in Section 6 hereof, or such other date and time as shall be mutually
agreed to by the Company and the Required Investors (the “Closing”). The date on which the Closing occurs
is hereinafter referred to as the “Closing Date.” At the Closing, (i) each Investor shall cause a wire
transfer in same day funds to be sent to the account of the Company as instructed in writing by the Company, in an amount
equal to the product of (A) the number of Units being purchased by such Investor on the Closing Date and (B) the Per Unit
Purchase Price, and (ii) the Company shall cause to be issued and delivered to each Investor or its designee, by FedEx or
other recognized overnight courier, Certificates or, if securities are issued in uncertificated form, written notice of
issuance, representing the Shares and the Warrants purchased by such Investor at the Closing, registered in such name or
names as such Investor may designate. The Closing shall take place at the offices of Weintraub Tobin Chediak Coleman &
Grodin Law Corporation, 400 Capital Mall, 11th Floor, Sacramento, California 95814 or at such other location and
on such other date as the Company and the Required Investors shall mutually agree.

 

    	4

    	 

    

 

4.         Representations and
Warranties of the Company. The Company hereby represents and warrants to the Investors that, except as may be set forth in
a separate written disclosure letter delivered to the Investors before the date of this Agreement (the “Disclosure Schedule”):

 

4.1.         Organization, Good
Standing and Qualification. Each of the Company and its Subsidiaries is a corporation duly organized, validly existing and
in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to
carry on its business as now conducted and to own or lease its properties. Each of the Company and its Subsidiaries is duly qualified
to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its
ownership or leasing of property makes such qualification or leasing necessary, unless the failure to so qualify has not had and
could not reasonably be expected to have a Material Adverse Effect. There are no Subsidiaries that are not included in the list
of the Company’s subsidiaries contained in Exhibit 23.1 to the Company’s Annual Report on Form 10-K for the fiscal
year ended March 31, 2014 (the “10-K”).

 

4.2.         Authorization.
The Company has full corporate power and authority and has taken all requisite action on the part of the Company, its officers,
directors and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization
of the performance of all obligations of the Company hereunder or thereunder, (iii) the authorization, issuance (or reservation
for issuance) and delivery of the Securities and (iv) to adopt and file the Certificate of Designation and perform its obligations
thereunder. The Transaction Documents constitute, or when executed and delivered by the Company will constitute, the legal, valid
and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting
creditors’ rights generally and to general equitable principles. The board of directors of the Company has determined, at
a duly convened meeting or pursuant to a unanimous written consent, that the issuance and sale of the Securities, and the consummation
of the transactions contemplated by the Certification of Designation, this Agreement and the other Transaction Documents (including
without limitation the issuance of the Conversion Shares and the Warrant Shares), are in the best interest of the Company.

 

4.3.         Due Execution; Enforceability.
This Agreement has been and, at or prior to the Closing, each other Transaction Document to be delivered at the Closing will be,
duly executed and delivered by the Company. This Agreement constitutes and, upon the execution and delivery thereof by the Company,
each other Transaction Document will constitute the valid and legally binding obligation of the Company, enforceable against it
in accordance with its terms, subject to (i) applicable bankruptcy, insolvency, fraudulent transfer, moratorium, reorganization
or other similar laws of general application relating to or affecting the enforcement of creditors’ rights generally and
(ii) general principles of equity.

 

    	5

    	 

    

 

4.4.         Capitalization; Debt.
The capitalization of the Company, including its authorized capital stock, the number of shares issued and outstanding, the number
of shares issuable and reserved for issuance pursuant to the Company’s stock option plans and agreements, the number of shares
issuable and reserved for issuance pursuant to securities (other than the Securities) exercisable for, or convertible into or exchangeable
for any shares of Common Stock is as set forth in the SEC Filings as of the dates set forth therein. All of the issued and outstanding
shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable and
free of pre-emptive rights and were issued in compliance in all respects with applicable state and federal securities law, except
as would not reasonably be expected to have a Material Adverse Effect. The Company owns all outstanding shares of each Subsidiary.
Except as reflected in the SEC Filings or in the Disclosure Schedule, no Person is entitled to pre-emptive rights with respect
to any securities of the Company. Except as reflected in the SEC Filings or in the Disclosure Schedule, there are no outstanding
warrants, options, convertible securities, or other rights, agreements or arrangements of any character under which the Company
or any of its Subsidiaries is or may be obligated to issue any material amounts of equity securities of any kind. Except as reflected
in the SEC Filings or in the Disclosure Schedule and except for the Registration Rights Agreement, there are no voting agreements,
buy-sell agreements, or right of first purchase agreements among the Company and any of the securityholders of the Company relating
to the securities of the Company held by them. Except as reflected in the SEC Filings or in the Disclosure Schedule and except
as provided in the Registration Rights Agreement, no Person has the right to require the Company to register any securities of
the Company under the 1933 Act. Except as reflected in the SEC Filings, the issuance and sale of the Securities hereunder will
not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors). Except
as reflected in the SEC Filings, the Company does not have outstanding stockholder rights plans or “poison pill” or
any similar arrangement in effect giving stockholders the right to purchase any equity interest in the Company upon the occurrence
of certain events. Except as disclosed in the SEC Filings, the Company has no material indebtedness outstanding as of the date
hereof.

 

4.5.         Valid Issuance.
The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued,
fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by the
Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws,
and will be delivered in compliance with all applicable federal and state securities laws. The Warrants have been duly and validly
authorized. Upon the due exercise of the Warrants or conversion of the Shares, the Warrant Shares and Conversion Shares (as the
case may be) will be validly issued, fully paid and non-assessable free and clear of all encumbrances and restrictions, except
for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws and except for those
created by the Investors, and will be delivered in compliance with all applicable federal and state securities laws. The Company
has reserved a sufficient number of shares of Common Stock for issuance upon conversion of the Shares and the exercise of the Warrants.

 

4.6.         Consents.
Except as reflected in the SEC Filings or in the Disclosure Schedule, the
execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the
Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or
official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant
to applicable state and federal securities laws which the Company undertakes to file within the applicable time periods.

 

    	6

    	 

    

 

4.7.         Delivery of SEC Filings;
Business. The Company has filed with the SEC all reports, schedules, registration statements and definitive proxy statements
that the Company was required to file with the SEC since April 1, 2012 (collectively, the “SEC Filings”). The
SEC Filings are the only filings required of the Company pursuant to the 1934 Act for such period. The Company is not aware of
any event occurring or expected to occur on or prior to the Closing Date (other than the transactions effected hereby and the next
Quarterly Report on Form 10-Q) that would require the filing of, or with respect to which the Company intends to file, a Current
Report on Form 8-K after the Closing. The Company and its Subsidiaries are engaged in all material respects only in the business
reflected in the SEC Filings, and the SEC Filings contain a complete and accurate description in all material respects of the business
of the Company and its Subsidiaries, taken as a whole.

 

4.8.         Use of Proceeds.
The net proceeds of the sale of the Units hereunder shall be used by the Company for general corporate purposes, which may include
without limitation working capital, capital expenditures, research and development expenditures, regulatory affairs expenditures,
clinical trial expenditures, acquisitions of or investments in new companies, technologies or products, and payment of indebtedness
or obligations.

 

4.9.         No Material Adverse
Change. Since March 31, 2014, except as reflected in the SEC Filings or as contemplated by the offer and sale of the Units,
there has not been:

 

(a)         any material adverse
change nor any material adverse development in the business, consolidated assets, liabilities, financial condition or operating
results of the Company;

 

(b)         any change by the Company
in its accounting principles, policies and methods except as required by changes in United States generally accepted accounting
principles applied on a consistent basis (“GAAP”) or applicable law.

 

(c)         any declaration or
payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the Company, or any
redemption or repurchase of any securities of the Company;

 

(d)         any material damage,
destruction or loss, whether or not covered by insurance, to any assets or properties of the Company or its Subsidiaries;

 

(e)         any waiver, not in
the ordinary course of business, by the Company or any Subsidiary of a material right or of a material debt owed to it;

 

(f)         any satisfaction or
discharge of any lien, claim or encumbrance or payment of any obligation by the Company or a Subsidiary, except in the ordinary
course of business;

 

    	7

    	 

    

 

(g)         any change or amendment
to the Company’s Restated Certificate of Incorporation or Bylaws, or material change to any Material Contract by which the Company
or any Subsidiary is bound or to which any of their respective assets or properties is subject;

 

(h)         any material labor
difficulties or labor union organizing activities with respect to employees of the Company or any Subsidiary;

 

(i)         any material transaction
entered into by the Company or a Subsidiary other than in the ordinary course of business;

 

(j)         the loss of the services
of any Key Employee, or material change in the composition or duties of the senior management of the Company or any Subsidiary;

 

(k)         the loss or threatened
loss of any customer which has had or could reasonably be expected to have a Material Adverse Effect; or

 

(l)         any action taken by
the by the Company or a Subsidiary to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization,
receivership, liquidation or winding up, nor does the Company or any Subsidiary have any knowledge or reason to believe that any
of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any facts which
would reasonably lead a creditor to do so; or

 

(m)         any other event or
condition of any character that has had or could reasonably be expected to have a Material Adverse Effect.

 

4.10.      SEC Filings.
At the time of filing thereof, the SEC Filings (including all exhibits and schedules thereto and the documents incorporated by
reference therein) complied in all material respects with the requirements of the 1933 Act or 1934 Act, as applicable, and the
rules and regulations promulgated thereunder, and did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. All documents required to be filed as exhibits to the SEC Filings have been filed as
required.

 

4.11.      No
Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the
Company and the issuance and sale of the Securities does not and will not (i) conflict with or result in a breach or
violation of (a) any of the terms and provisions of, or constitute a default under the Company’s Restated Certificate
of Incorporation or the Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have
been made available to the Investors through the EDGAR system), or (b) to any statute, rule, regulation or order of any
governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company, any Subsidiary or any of
their respective assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse
of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon
any of the properties or assets of the Company or any Subsidiary or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract, except, in the case
of clauses (i)(b) and (ii) only, for such conflicts, breaches, violations and defaults as have not had, and could not
reasonably be expected to have, a Material Adverse Effect, individually or in the aggregate.

 

    	8

    	 

    

 

4.12.      Tax Matters.
The Company and each Subsidiary has timely prepared and filed all material tax returns required to have been filed by the Company
or such Subsidiary with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it,
except as could not reasonably be expected to have a Material Adverse Effect. The charges, accruals and reserves on the books of
the Company in respect of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid
assessments against the Company or any Subsidiary nor, to the Company’s Knowledge, any basis for the assessment of any additional
taxes, penalties or interest for any fiscal period or audits by any federal, state or local taxing authority, except for any assessment
which could not be reasonably expected to have a Material Adverse Effect. All material taxes and other assessments and levies that
the Company or any Subsidiary is required to withhold or to collect for payment have been duly withheld and collected and paid
to the proper governmental entity or third party when due. There are no material tax liens or claims pending or, to the Company’s
Knowledge, threatened against the Company or any Subsidiary or any of their respective assets or property. Except as reflected
in the SEC Filings, there are no outstanding tax sharing agreements or other such arrangements between the Company and any Subsidiary
or other corporation or entity. The Company has not participated in a “listed transaction” within the meaning of Treasury
Regulation Section 1.6011-4(b)(2).

 

4.13.      Title to Properties.
Except as reflected in the SEC Filings, the Company and each Subsidiary has good and marketable title to all real properties and
all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would materially affect
the value thereof or materially interfere with the use made or currently planned to be made thereof by them; and except as reflected
in the SEC Filings, the Company and each Subsidiary holds any leased real or personal property under valid and enforceable leases
with no exceptions that would materially interfere with the use made or currently planned to be made thereof by them.

 

4.14.      Certificates, Authorities
and Permits. The Company and each Subsidiary possess all material certificates, authorities and permits issued by appropriate
governmental agencies or bodies necessary to conduct the business now operated by it, and neither the Company nor any Subsidiary
has received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit
that, if determined adversely to the Company or such Subsidiary, could reasonably be expected to have a Material Adverse Effect,
individually or in the aggregate.

 

4.15.       Labor
Matters.

 

(a)         The
Company is not a party to or bound by any collective bargaining agreements or other agreements with labor organizations. The
Company has not violated in any material respect any laws, regulations, orders or contract terms, affecting the collective bargaining rights
of employees, labor organizations or any laws, regulations or orders affecting employment discrimination, equal opportunity
employment, or employees’ health, safety, welfare, wages and hours.

 

    	9

    	 

    

 

(b)         (i)         There
are no labor disputes existing, or to the Company’s Knowledge, threatened, involving strikes, slow-downs, work stoppages, job actions,
disputes, lockouts or any other disruptions of or by the Company’s employees, (ii) there are no unfair labor practices or petitions
for election pending or, to the Company’s Knowledge, threatened before the National Labor Relations Board or any other federal,
state or local labor commission relating to the Company’s employees, (iii) no demand for recognition or certification heretofore
made by any labor organization or group of employees is pending with respect to the Company and (iv) to the Company’s Knowledge,
the Company enjoys good labor and employee relations with its employees and labor organizations.

 

(c)         The
Company is, and at all times has been, in compliance in all material respects with all applicable laws respecting employment (including
laws relating to classification of employees and independent contractors) and employment practices, terms and conditions of employment,
wages and hours, and immigration and naturalization. There are no claims pending against the Company before the Equal Employment
Opportunity Commission or any other administrative body or in any court asserting any violation of Title VII of the Civil Rights
Act of 1964, the Age Discrimination Act of 1967, 42 U.S.C. §§ 1981 or 1983 or any other federal, state or local Law,
statute or ordinance barring discrimination in employment.

 

(d)         Except
as reflected in the SEC Filings, the Company is not a party to, or bound by, any employment or other contract or agreement that
contains any severance, termination pay or change of control liability or obligation, including, without limitation, any “excess
parachute payment,” as defined in Section 280G(b) of the Internal Revenue Code.

 

(e)         To
the Company’s Knowledge, each of the Company’s employees is a Person who is either a United States
citizen or a permanent resident entitled to work in the United States. To the Company’s Knowledge, the Company has no liability
for the improper classification by the Company of such employees as independent contractors or leased employees prior to the Closing,
except as could not reasonably be expected to have a Material Adverse Effect.

 

4.16.       Intellectual Property.
Except as reflected in the SEC Filings:

 

(a)         All material Intellectual
Property of the Company and its Subsidiaries is currently in compliance with all legal requirements (including timely filings,
proofs and payments of fees) and is valid and enforceable, except as would not reasonably be expected to have a Material Adverse
Effect. No Intellectual Property of the Company or its Subsidiaries which is material to the Company and necessary for the conduct
of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to
be conducted is involved in any cancellation, dispute or litigation, and, to the Company’s Knowledge, no such action is threatened.
No patent owned by the Company or its Subsidiaries is involved in any interference, reissue, re-examination or opposition proceeding.

 

    	10

    	 

    

 

(b)         All of the licenses
and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are material to the Company and
necessary for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted
or as currently proposed to be conducted to which the Company or any Subsidiary is a party or by which any of their assets are
bound (other than generally commercially available, non-custom, off-the-shelf software application programs having a retail acquisition
price of less than $10,000 per license) (collectively, “License Agreements”) are valid and binding obligations
of the Company or its Subsidiaries that are parties thereto and, to the Company’s Knowledge, the other parties thereto, enforceable
in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally, and to
the Company’s Knowledge there exists no event or condition which will result in a material violation or breach of or constitute
(with or without due notice or lapse of time or both) a default by the Company or any of its Subsidiaries under any such License
Agreement, in each case that would reasonably be expected to have a Material Adverse Effect.

 

(c)         The Company and its
Subsidiaries own or have the valid right to use all of the material Intellectual Property that is necessary for the conduct of
the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to
be conducted and for the ownership, maintenance and operation of the Company’s and its Subsidiaries’ properties and
assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property
and Confidential Information, other than licenses entered into in the ordinary course of the Company’s and its Subsidiaries’
businesses. To the Company’s Knowledge, the Company and its Subsidiaries have a valid and enforceable right to use all material
third party Intellectual Property and Confidential Information used or held for use in the respective businesses of the Company
and its Subsidiaries, except as would not reasonably be expected to have a Material Adverse Effect.

 

(d)         All material licenses
or other material agreements under which the Company is granted Intellectual Property are in full force and effect and, to the
Company’s Knowledge, there is no material default by any other party thereto. The Company has no reason to believe that the
licensors under such licenses and other agreements do not have and did not have all requisite power and authority to grant the
rights to the Intellectual Property purported to be granted thereby.

 

(e)         To
the Company’s Knowledge (without having conducted any specific investigation), the conduct of the Company’s and
its Subsidiaries’ businesses as currently conducted does not infringe or otherwise impair or conflict with in any
material respect (collectively, “Infringe”) any Intellectual Property rights of any third party or any
confidentiality obligation owed to a third party except as could not reasonably be expected to have a Material Adverse
Effect, and, to the Company’s Knowledge the Intellectual Property and Confidential Information of the Company and its
Subsidiaries which are material to the Company and necessary for the conduct of Company’s and each of its
Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted are not being
Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s Knowledge,
threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of
any Intellectual Property or Confidential Information of the Company and its Subsidiaries and the Company’s and its
Subsidiaries’ use of any Intellectual Property or Confidential Information owned by a third party, and, to the
Company’s Knowledge, there is no valid basis for the same.

 

    	11

    	 

    

 

(f)         The consummation of
the transactions contemplated hereby and by the other Transaction Documents will not result in the alteration, loss, impairment
of or restriction on the Company’s or any of its Subsidiaries’ ownership or right to use any of the Intellectual Property
or Confidential Information which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective
businesses as currently conducted or as currently proposed to be conducted.

 

(g)         The Company has taken
reasonable steps to protect the Company’s and its Subsidiaries’ rights in their Intellectual Property and Confidential
Information. Neither the Company nor, to the Company’s Knowledge, any of its employees has any agreements or arrangements
with former employers of such employees relating to any Intellectual Property of such employers, which materially interfere or
conflict with the performance of such employee’s duties for the Company or result in any former employers of such employees
having any rights in, or claims on, the Company’s Intellectual Property. Each current and former employee, consultant and
contractor who has had access to Confidential Information which is material to the Company and necessary for the conduct of Company’s
and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted has executed
an agreement or is otherwise under an obligation to maintain the confidentiality of such Confidential Information, and the Company
has not received written notice that any employee, consultant or independent contractor is in violation of any agreement or in
breach of any agreement or arrangement with former or present employers relating to proprietary information or assignment of inventions.
Without limiting the foregoing: (i) the Company has taken reasonable security measures to guard against unauthorized disclosure
or use of any of its Intellectual Property and (ii) the Company has no reason to believe that any Person (including, without limitation,
any former employee or consultant of the Company) has unauthorized possession of any of its Intellectual Property, or any part
thereof, or that any Person has obtained unauthorized access to any of its Intellectual Property. To the Company’s Knowledge,
the Company is not making any material unlawful use of any Intellectual Property of any other Person, including, without limitation,
any former employer of any past or present employees of the Company.

 

4.17.       Environmental Matters.
To the Company’s Knowledge, neither the Company nor any Subsidiary is in violation of any statute, rule, regulation, decision
or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous
or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances
(collectively, “Environmental Laws”), owns or operates any real property contaminated with any substance that
is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws,
or is subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim has had or could
reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or, to the
Company’s Knowledge, threatened investigation that might lead to such a claim.

 

    	12

    	 

    

 

4.18.       Litigation.
Except as reflected in the SEC Filings, there are no material pending actions, suits or proceedings against or affecting the Company,
its Subsidiaries or any of its or their properties; and to the Company’s Knowledge, no such actions, suits or proceedings
are threatened or contemplated. Except as reflected in the Company’s previous annual reports on Form 10-K, neither the Company
nor any Subsidiary, nor to the Company’s Knowledge any director, officer or employee thereof, is or since April 1, 2009 has
been the subject of any action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty. There has not been, and to the Company’s Knowledge there is not pending or contemplated, any
investigation by the SEC involving the Company or any current or former director or officer of the Company. The SEC has not issued
any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the 1933 Act or the 1934 Act.

 

4.19.       Financial Statements.
The financial statements included in each SEC Filing comply in all material respects with applicable accounting requirements and
the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent
restatement) and present fairly, in all material respects, the consolidated financial position of the Company as of the dates shown
and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been prepared
in conformity with GAAP (except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements,
as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial statements in the SEC Filings, the Company
has no liabilities, contingent or otherwise, other than liabilities incurred in the ordinary course of business which, under GAAP,
are not required to be reflected in the financial statements included in each SEC Filing and which, individually or in the aggregate,
are not material to the business or financial condition of the Company.

 

4.20.       Nasdaq Compliance.
The Common Stock is registered pursuant to Section 12(g) of the 1934 Act and is listed on The NASDAQ Capital Market (the “Nasdaq
CM”) maintained by NASDAQ Stock Market LLC (“NASDAQ”), and the Company has taken no action designed
to, or likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act or removal from quotation
of the Common Stock from the Nasdaq CM, nor has the Company received any notification that the SEC, NASDAQ or the Financial Industry
Regulatory Authority, Inc. is contemplating terminating such registration or quotation.

 

4.21.       No Directed Selling
Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf (i) has conducted any general solicitation
or general advertising (as those terms are used in Regulation D) in connection with the transactions contemplated by this Agreement
or (ii) has, directly or indirectly, made any offers or sales of any security or the right to purchase any security, or solicited
any offers to buy any security or any such right, under circumstances that would require registration of the Securities under the
1933 Act.

 

4.22.       Private Placement.
Assuming the accuracy of the representations and warranties of the Investors contained in Section 5 hereof and compliance by the
Investors with the terms of the Transaction Documents, the offer and sale of the Securities to the Investors as contemplated hereby
is exempt from the registration requirements of the 1933 Act.

 

    	13

    	 

    

 

4.23.       Questionable Payments.
Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of their respective current
or former directors, officers, employees, agents or other Persons acting on behalf of the Company or any Subsidiary, has on behalf
of the Company or any Subsidiary or in connection with their respective businesses: (a) used any corporate funds for unlawful contributions,
gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payments
to any governmental officials or employees from corporate funds; (c) established or maintained any unlawful or unrecorded
fund of corporate monies or other assets; (d) made any false or fictitious entries on the books and records of the Company or any
Subsidiary; (e) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature; or
(f) violated any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

4.24.       Transactions with
Affiliates. Except as reflected in the SEC Filings, none of the officers or directors of the Company and, to the Company’s
Knowledge, none of the employees of the Company is presently a party to any material transaction with the Company or any Subsidiary
(other than as holders of stock options and/or warrants, and for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s
Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director,
trustee or partner.

 

4.25.       Internal Controls.
Except as reflected in the SEC Filings (including under Item 9A of the 10-K), the Company and
the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets
is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The
Company has established disclosure controls and procedures (as defined in 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company
and designed such disclosure controls and procedures to ensure that material information relating to the Company, including the
Subsidiaries, is made known to the certifying officers by others within those entities, during the period in which the Company’s
most recently filed periodic report under the 1934 Act is being prepared. The Company’s certifying officers have evaluated the
effectiveness of the Company’s controls and procedures as of the end of the period covered by the most recently filed periodic
report under the 1934 Act (such date, the “Evaluation Date”). The Company presented in its most recently filed
periodic report under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant
changes in the Company’s internal controls (as such term is defined in Item 308 of Regulation S-K) or, to the Company’s Knowledge,
in other factors that could significantly affect the Company’s internal controls.

 

4.26.       Investment
Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately following the
Closing will not be required to register as, an “investment company” within the meaning of the Investment Company
Act of 1940, as amended, and shall conduct its business in a manner so that it will not become subject to the Investment
Company Act.

 

    	14

    	 

    

 

4.27.       Key Employees.
Each of the Company’s executive officers (as defined in Rule 405 under the 1933 Act) (each, a “Key Employee”)
is currently serving in the capacity described in the SEC Filings. The Company has no knowledge of any fact or circumstance (including
without limitation (i) the terms of any agreement to which such person is a party or any litigation in which such person is or
may become involved and (ii) any illness or medical condition that could reasonably be expected to result in the disability or
incapacity of such person) that would limit or prevent any such person from serving in such capacity on a full-time basis in the
foreseeable future, or of any intention on the part of any such person to limit or terminate his or her employment with the Company.

 

4.28.       ERISA. The Company
does not maintain or contribute to, or have any obligation under, any Pension Plan. The Company is in compliance in all material
respects with the presently applicable provisions of ERISA and the United States Internal Revenue Code of 1986, as amended, except
for matters that, individually or in the aggregate, have not had, and would not reasonably be expected to have, a Material Adverse
Effect.

 

4.29.       Form S-3. The
Company is eligible to register the Registrable Securities for resale by the Investors on a registration statement on Form S-3
under the 1933 Act. To the Company’s Knowledge, there exist no facts or circumstances (including without limitation any required
approvals or waivers of any circumstances that may delay or prevent the obtaining of accountant’s consents) that could reasonably
be expected to prohibit or delay the preparation, filing or effectiveness of such registration statement.

 

4.30.       Fees. Except
as reflected in the Disclosure Schedule or as contemplated by Section 9.6 hereof, the Company is not obligated to pay any compensation
or other fee, cost or related expenditure to any underwriter, broker, agent or other representative in connection with the transactions
contemplated by this Agreement. The Company will indemnify and hold harmless the Investors from and against any claim against the
Investors by any Person alleging that, as a result of any agreement or arrangement between such Person and the Company, the Investors
is obligated to pay any such compensation fee, cost or related expenditure in connection with the transactions contemplated hereby
or the other Transaction Documents.

 

4.31.       Insurance. The
Company maintains insurance in such amounts and covering such losses and risks as the Company believes to be reasonably prudent
in relation to the businesses in which the Company is engaged. No notice of cancellation has been received for any of such policies
and the Company is in compliance with all of the terms and conditions thereof. The Company has no reason to believe that it will
not be able to renew any existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue doing business as currently conducted without a significant increase in cost, other than
normal increases in the industry. Without limiting the generality of the foregoing, the Company maintains directors and officers
insurance in an amount deemed to be reasonable and appropriate by the Company’s board of directors.

 

    	15

    	 

    

 

4.32.       Transfer Taxes.
No stock transfer or other taxes (other than income taxes) are required to be paid in connection with the issuance and sale of
any of the Securities.

 

4.33.       Off Balance Sheet
Arrangements. There is no transaction, arrangement or other relationship between the Company or any of its Subsidiaries and
an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings and
is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

4.34.       Embargoed Person.
None of the funds or other assets of the Company shall constitute property of, or shall be beneficially owned, directly or indirectly,
by any person subject to trade restrictions under United States law, including, but not limited to, the International Emergency
Economic Powers Act, 50 U.S.C. § 1701 et seq., The Trading with the Enemy Act, 50 U.S.C. App. 1 et seq., and
any Executive Orders or regulations promulgated under any such United States laws (each, an “Embargoed Person”),
with the result that the investments evidenced by the Securities are or would be in violation of law. No Embargoed Person shall
have any interest of any nature whatsoever in the Company with the result that the investments evidenced by the Securities are
or would be in violation of law. None of the funds or other assets of the Company shall be derived from any unlawful activity with
the result that the investments evidenced by the Securities are or would be in violation of law.

 

4.35.       Solvency. After
giving effect to the transactions contemplated by this Agreement, (i) the fair saleable value of the Company’s assets exceeds
the amount that will be required to be paid on or in respect of the Company’s existing indebtedness as such indebtedness
matures or is otherwise payable and (ii) the current cash flow of the Company, together with the proceeds the Company would receive
upon liquidation of its assets, after taking into account all anticipated uses of such amounts, would be sufficient to pay all
indebtedness when such indebtedness is required to be paid. The Company has no knowledge of any facts or circumstances which lead
it to believe that it will be required to file for reorganization or liquidation under the bankruptcy or reorganization laws of
any jurisdiction, and has no present intention to so file.

 

4.36.       Customers. The
relationships of the Company with its customers are maintained on commercially reasonable terms. To the Company’s Knowledge,
no customer of the Company has any plan or intention to terminate its agreement with the Company, which termination would reasonably
be expected to have a Material Adverse Effect.

 

4.37.       Acknowledgement
of Dilution. The Company acknowledges that the issuance of the Conversion Shares upon conversion of the Preferred Shares and
issuance of Warrant Shares upon exercise of the Warrants may result in dilution of the outstanding shares of Common Stock. The
Company further acknowledges that its obligation to issue Conversion Shares and Warrant Shares in accordance with the terms of
the Certificate of Designation and Warrants, respectively, is unconditional regardless of the effect of any such dilution.

 

    	16

    	 

    

 

4.38.       Full
Disclosure. The representations, warranties and written statements contained in this Agreement and the other Transaction
Documents and in the certificates, exhibits and schedules delivered to such Investors by the Company pursuant to this
Agreement and the other Transaction Documents and in connection with such Investor’s due diligence investigation of the
Company, do not contain any untrue statement of a material fact, and do not omit to state a material fact required to be
stated therein or necessary in order to make such representations, warranties or statements not misleading in light of the
circumstances under which they were made. Neither the Company nor any Person acting on its behalf or at its direction has
provided such Investor with material non-public information. The Company acknowledges that such Investor is relying on the
representations, acknowledgments and agreements made by the Company in this Section and elsewhere in this Agreement in making
trading and other decisions concerning the Company’s securities.

 

4.39.       Application of Takeover
Protections. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other
similar anti-takeover provision under the Company’s charter or the laws of its state of incorporation that is or could become
applicable to the Investors as a result of the Investors and the Company fulfilling their respective obligations or exercising
their respective rights under the Transaction Documents (as applicable), including, without limitation, as a result of the Company’s
issuance of the Securities and the Investors’ ownership of the Securities.

 

4.40.       Acknowledgement
Regarding Investors’ Acquisition of Securities. The Company acknowledges and agrees that the Investors are acting solely
in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated by the Transaction
Documents. The Company further acknowledges that the Investors are not acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to this Agreement and the transactions contemplated by the Transaction Documents, and
any advice given by the Investors or any of its representatives or agents in connection therewith is merely incidental to the Investors’
acquisition of the Securities. The Company further represents to the Investors that the Company’s decision to enter into
the Transaction Documents to which it is a party has been based solely on the independent evaluation of the transactions contemplated
thereby by the Company and its representatives. The Company acknowledges and agrees that the Investors have not made and does not
make any representations or warranties with respect to the transactions contemplated by the Transaction Documents other than those
specifically set forth in Section 5 of this Agreement.

 

5.         Representations and
Warranties of the Investors. Each Investor hereby represents and warrants to the Company that:

 

5.1.         Organization and
Existence. Such Investor is a validly existing corporation, limited partnership or limited liability company and has all requisite
corporate, partnership or limited liability company power and authority to invest in the Securities pursuant to this Agreement.

 

5.2.         Authorization.
The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor is a party have
been duly authorized and each constitutes, or upon execution and delivery thereof by such Investor will constitute, the valid
and legally binding obligation of such Investor, enforceable against such Investor in accordance with their respective terms,
subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability,
relating to or affecting creditors’ rights generally.

 

    	17

    	 

    

 

5.3.         Purchase Entirely
for Own Account. The Securities to be received by such Investor hereunder will be acquired for such Investor’s own account,
not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and
such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation
of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell
or otherwise dispose of all or any part of such Securities in compliance with applicable
federal and state securities laws. Nothing contained herein shall be deemed a representation
or warranty by such Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer registered
with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered.

 

5.4.         Investment Experience.
Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such
knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment
contemplated hereby.

 

5.5.         Disclosure of Information.
Such Investor has had an opportunity to receive all information related to the Company requested by it and to ask questions of
and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities.
Such Investor acknowledges receipt of copies of the SEC Filings. Neither such inquiries nor any other due diligence investigation
conducted by such Investor shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations
and warranties contained in this Agreement.

 

5.6.         Restricted Securities.
Such Investor understands that the Securities are characterized as “restricted securities” under the U.S. federal securities
laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such
laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances.

 

5.7.         Legends. It is
understood that certificates evidencing the Securities may bear the following or any similar legend (and if Securities are issued
in uncertificated form, the Company may impose comparable restrictions on such uncertificated securities):

 

(a)         “The securities
represented hereby have not been registered with the Securities and Exchange Commission or the securities commission of any state
in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be transferred,
unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, or (ii) such securities
may be sold pursuant to Rule 144 or other applicable exemption from applicable securities laws. The issuer may require an opinion
of counsel to the holder of these securities, in form and substance reasonably satisfactory to the issuer, that such transfer may
lawfully be made without registration under the Securities Act of 1933, as amended.”

 

    	18

    	 

    

 

(b)         If required by the
authorities of any state in connection with the issuance of sale of the Securities, the legend required by such state authority.

 

5.8.         Accredited Investor.
Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act, as amended by
the Dodd-Frank Wall Street Reform and Consumer Protection Act.

 

5.9.         Brokers and Finders.
No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim
against or upon the Company, any Subsidiary or an Investor for any commission or fee pursuant to any agreement, arrangement or
understanding entered into by or on behalf of such Investor.

 

6.         Conditions to Closing.

 

6.1.         Conditions to the
Investors’ Obligations. Each Investor’s obligation to purchase the Shares and the Warrants at the Closing is subject
to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of
which may be waived by the Investor:

 

(a)         The representations
and warranties made by the Company in Section 4 hereof qualified as to materiality shall be true and correct at all times prior
to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in
which case such representation or warranty shall be true and correct as of such earlier date, and, the representations and warranties
made by the Company in Section 4 hereof not qualified as to materiality shall be true and correct in all material respects at all
times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier
date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date.
The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on
or prior to the Closing Date.

 

(b)         The Company shall have
obtained any and all material consents, permits, approvals, registrations and waivers that are necessary for consummation of the
purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents, all
of which shall be in full force and effect.

 

(c)         The Company shall have
executed and delivered the Registration Rights Agreement.

 

(d)         The Certificate of
Designation shall have been filed with the Delaware Secretary of State, and delivered to such Investor written evidence of the
acceptance of such filing.

 

(e)         The Company shall have
delivered to such Investor duly executed Warrants and certificates representing the Preferred Shares being purchased by such Investor
at the Closing.

 

    	19

    	 

    

 

(f)         No judgment, writ,
order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge,
or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted
by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other
Transaction Documents.

 

(g)         The Company shall have
delivered to such Investor a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial
Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a) and (b) of
this Section 6.1.

 

(h)         The Company shall have
delivered to such Investor a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date, certifying
the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and
the other Transaction Documents and the issuance of the Securities, certifying the current versions of the Restated Certificate
of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction
Documents and related documents on behalf of the Company.

 

(i)         The Investor shall
have received an opinion from Weintraub Tobin Chediak Coleman Grodin Law Corporation, the Company’s counsel, dated as of
the Closing Date, in form and substance reasonably acceptable to the Required Investors and addressing such legal matters as the
Required Investors may reasonably request.

 

(j)         No stop order or suspension
of trading shall have been imposed by the SEC or any other governmental or regulatory body with respect to public trading in the
Common Stock.

 

(k)         The Company shall have
authorized and reserved for issuance the aggregate number of shares of Common Stock issuable upon the exercise of Warrants to be
issued at the Closing.

 

(l)         There shall be no injunction,
restraining order or decree of any nature of any court or governmental authority of competent jurisdiction that is in effect that
restrains or prohibits the consummation of the transaction contemplated hereby and by the other Transaction Documents.

 

(m)         There shall not have
occurred any material adverse change in the Company’s consolidated business or financial condition since the date of the
Company’s most recent SEC Filing.

 

(n)         The Common Stock shall
be listed on the NASDAQ CM.

 

6.2.         Conditions to Obligations
of the Company. The Company’s obligation to sell and issue the Shares and the Warrants at the Closing is subject to the
fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be
waived by the Company:

 

    	20

    	 

    

 

(a)         The representations and
warranties made by the Investors in Section 5 hereof shall be true and correct in all material respects when made, and shall
be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and
as of said date. The Investors shall have performed in all material respects all obligations and covenants herein required to be
performed by it on or prior to the Closing Date.

 

(b)         The Investors shall
have executed and delivered the Registration Rights Agreement.

 

(c)         The Investors shall
have paid in full the purchase price for the Units purchased by the Investors hereunder.

 

6.3.         Termination of Obligations
to Effect Closing; Effects.

 

(a)         The obligations of
the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:

 

(i)         Upon the mutual written
consent of the Company and the Investors;

 

(ii)        By the Company if any
of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been waived by the Company;

 

(iii)       By the Investors if
any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived
by the Investors; or

 

(iv)       By either the Company
or the Investors if the Closing has not occurred on or prior to August 31, 2014;

 

provided, however, that, except in the case of
clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its
representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach
has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect the Closing.

 

(b)         Nothing in this Section
6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement
or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its
obligations under this Agreement or the other Transaction Documents.

 

    	21

    	 

    

 

7.         Covenants and Agreements
of the Company.

 

7.1.         Reservation
of Common Stock. The Company shall, on the Closing Date and at all times thereafter, reserve and keep available out of
its authorized but unissued shares of Common Stock, solely for the purpose of providing for the conversion of the Shares and
exercise of the Warrants, such number of shares of Common Stock as shall from time to time equal the number of shares
sufficient to permit the conversion of the Shares and the exercise of the Warrants issued pursuant to this Agreement in
accordance with their respective terms (the “Reserved Amount”). While the Warrants are outstanding, the
Company shall not reduce the Reserved Amount without obtaining prior written consent of the Investors.

 

7.2.         No Conflicting Agreements.
The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material
respect with the Company’s obligations to the Investors under the Transaction Documents.

 

7.3.         Removal
of Legends. The Company shall, no later than three Trading Days following the delivery by an Investor to the Company or
the Company’s transfer agent (with notice to the Company) of (i) a notice that any of the Securities held by an
Investor have been or will be sold pursuant to a registration statement or Rule 144 under the 1933 Act or are eligible for
sale without restriction under Rule 144 or that such legend is not otherwise required, (ii) in the case of a Rule 144
transaction, a representation by such Investor and such Investor’s broker, as applicable, that the requirements of Rule
144, as applicable and if required, have been satisfied and (iii) a legended certificate representing such Securities
(endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance
and/or transfer, if applicable), as directed by the Investor, either: (A) issue and deliver (or cause to be issued and
delivered) to the Investor a certificate representing such Securities that is free from all restrictive and other legends or
(B) cause the Company’s transfer agent to credit the Investor’s or its designee’s account at DTC through
its Deposit/Withdrawal at Custodian (DWAC) system with a number of shares of Common Stock equal to the number of Securities
represented by the certificate so delivered by the Investor (the date by which such certificate is required to be delivered
to the Investor or such credit is so required to be made to the account of the Investor or its designee at DTC pursuant to
the foregoing is referred to herein as the “Required Delivery Date”). If the Company fails on or prior to
the Required Delivery Date to either (i) issue and deliver (or cause to be issued and delivered) to the Investor a
certificate representing the Securities that is free from all restrictive and other legends or (ii) cause the
Company’s transfer agent to credit the balance account of the Investor or its designee at DTC through its
Deposit/Withdrawal at Custodian (DWAC) system with a number of shares of Common Stock equal to the number of Securities
represented by the certificate delivered by the Investor pursuant hereto, then, in addition to all other remedies available
to the Investor, the Company shall pay in cash to the Investor on each day after the Required Delivery Date that the issuance
or credit of such shares is not timely effected an amount equal to 1.0% (increasing to 2.0% if shares are not delivered
following the tenth (10) Trading Day) of the product of (A) the sum of the number of Securities not issued to the Investor on
a timely basis and to which the Investor is entitled and (B) the VWAP for the five Trading Day period immediately preceding
the Required Delivery Date. In addition to the foregoing, if the Company fails to so properly deliver such unlegended
certificates or so properly credit the account of the Investor or its designee at DTC by the Required Delivery Date, and if
on or after the Required Delivery Date the Investor purchases (in an open market transaction or otherwise) shares of Common
Stock to deliver in satisfaction of a sale by the Investor of shares of Common Stock that the Investor anticipated receiving
from the Company without any restrictive legend, then the Company shall, within three Trading Days after the Investor’s
request, pay cash to the Investor in an amount equal to the Investor’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased, at which point the Company’s obligation to deliver a
certificate or credit such Investor’s or its designee’s account at DTC for such shares of Common Stock shall
terminate and such shares shall be cancelled.

 

    	22

    	 

    

 

7.4.         Equal Treatment of
Investors. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision
of this Agreement or any of the other Transaction Documents, unless the same consideration is also offered to all of the parties
thereto. For clarification purposes, this provision constitutes a separate right granted to the Investors by the Company and negotiated
separately by the Investors, and is intended for the Company to treat the Investors as a class and shall not in any way be construed
as such Persons acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

7.5.         Non-Public Information.
Upon delivery by the Company to an Investor after the Closing Date of any notice or information, in writing, electronically or
otherwise, and while Securities are held by such Investor, unless the Company has in good faith determined that the matters relating
to such notice or information do not constitute material, nonpublic information relating to the Company or unless such information
is delivered to such Investor pursuant to a nondisclosure agreement between the Company and such Investor whereby such Investor
has agreed to maintain material nonpublic information in confidence, the Company shall within four (4) days after any such delivery
publicly disclose such material, nonpublic information on a Report on Form 8-K. In the event that the Company believes that a notice
or communication to an Investor contains material, nonpublic information relating to the Company, the Company shall so indicate
to the Investor prior to delivery of such notice or information. In the absence of any such Company indication, the Investor shall
be allowed to presume that all matters relating to such notice and information do not constitute material, nonpublic information
relating to the Company. The Investor shall have five (5) days to notify the Company that Investor elects not to receive such information.
In the case that Investor elects not to receive such information, the Company will not deliver such information to such Investor;
provided that such failure to provide such information will not be deemed to be a default by the Company under the Transaction
Documents. If the Investor does not make such an election, then the Investor agrees to maintain any material nonpublic information
so disclosed by the Company in confidence.

 

7.6.         Conduct
of Business. For so long as the Warrants remain outstanding, the Company agrees that it will (i) maintain its corporate
existence in good standing, (ii) comply in all material respects with all laws, rules, ordinances and regulations of all
governmental authorities, (iii) maintain, keep and preserve all of its properties necessary in the proper conduct of its
businesses in good repair, working order and condition (ordinary wear and tear excepted) and make all necessary repairs,
renewals and replacements and improvements thereto, except where the failure to do so would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect, (iv) pay or discharge before becoming delinquent (a) all
taxes, levies, assessments and governmental charges imposed on it or its income or profits or any of its property and (b) all
lawful claims for labor, material and supplies, which, if unpaid, might become a lien upon any of its property, except in
each of the above instances where the failure to do so would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect, (iv) timely file with the SEC all reports required to be filed pursuant to the 1934 Act
and refrain from terminating its status as an issuer required by the 1934 Act to file reports thereunder even if the 1934 Act
or the rules or regulations thereunder would permit such termination.

 

    	23

    	 

    

 

7.7.         Use of Proceeds.
The Company shall use the proceeds from the sale of the Securities as set forth in Section 4.8; provided, however,
that the Company shall not use such proceeds (i) to pay any dividend or make any distribution on any such securities, or (ii) to
repay any loan made to or incurred by any Key Employee or Affiliate of the Company.

 

7.8.         Listing. The
Company (i) has, or promptly following the Closing shall, use its best efforts to include all of the Conversion Shares issuable
upon conversion of the Preferred Shares and all of the Warrant Shares issuable upon exercise of the Warrants (without regard to
any limitation on such conversion or exercise) for listing on the NASDAQ CM, and (ii) shall use its best efforts to maintain the
designation and quotation, or listing, of the Common Stock on the NASDAQ CM following the Closing Date.

 

8.         Survival, Indemnification
and Remedies.

 

8.1.         Survival. The
representations, warranties, covenants, indemnities and agreements contained in this Agreement, in the Certificate of Designation
and in the other Transaction Documents shall survive the Closing of the transactions contemplated by this Agreement.

 

8.2.         Indemnification.
In consideration of an Investor’s execution and delivery of this Agreement and acquiring the Securities hereunder and
in addition to all of the Company’s other obligations under the Transaction Documents to which it is a party, subject
to the provisions of this Section 8.2, the Company shall indemnify and hold harmless each Investor, each of its directors,
officers, shareholders, members, partners, employees, representatives, agents and advisors (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title), each
Person, if any, who controls the Investor (within the meaning of Section 15 of the 1933 Act or Section 20(a) of the 1934
Act), and the respective directors, officers, shareholders, members, partners, employees, representatives, agents and
advisors (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack
of such title or any other title) of such controlling Persons (each, an “Investor Party”), from and
against all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses (including all judgments,
amounts paid in settlement, court costs, reasonable attorneys’ fees and costs of defense and investigation)
(collectively, “Damages”) that any Investor Party may suffer or incur as a result of or relating to (a)
any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the
other Transaction Documents to which it is a party or (b) any action, suit, claim or proceeding (including for these purposes
a derivative action brought on behalf of the Company) instituted against such Investor Party arising out of or resulting from
the execution, delivery, performance or enforcement of the Transaction Documents, other than claims for
indemnification within the scope of Section 6 of the Registration Rights Agreement; provided, however, that (x)
the foregoing indemnity shall not apply to any Damages to the extent, but only to the extent, that such Damages resulted
directly and primarily from a breach of any of the Investor’s representations, warranties, covenants or agreements
contained in this Agreement or the Registration Rights Agreement, and (y) the Company shall not be liable under this Section
8.2 to the extent, but only to the extent, that a court of competent jurisdiction shall have determined by a final judgment
(from which no further appeals are available) that such Damages resulted directly and primarily from any acts or failures to
act, undertaken or omitted to be taken by such Investor Party through its fraud, bad faith, gross negligence, or willful or
reckless misconduct.

 

    	24

    	 

    

 

An Investor Party’s
right to indemnification or other remedies based upon the representations, warranties, covenants and agreements of the Company
set forth in the Transaction Documents shall not in any way be affected by any investigation or knowledge of such Investor Party.
Such representations, warranties, covenants and agreements shall not be affected or deemed waived by reason of the fact that an
Investor Party knew or should have known that any representation or warranty might be inaccurate or that the Company failed to
comply with any agreement or covenant. Any investigation by such Investor Party shall be for its own protection only and shall
not affect or impair any right or remedy hereunder.

 

To the extent that the
foregoing undertakings by the Company set forth in this Section 8.2 may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Damages which is permissible under applicable law.

 

8.3.         Conduct of Indemnification
Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification
hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses
of such counsel shall be at the expense of such person, unless (a) the indemnifying party has agreed to pay such fees or expenses,
or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory
to such person, or (c) in the reasonable judgment of any such person, a conflict of interest may exist between such person and
the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that
such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the
right to assume the defense of such claim on behalf of such person), or (d) if such Claim seeks any equitable relief or alleges
any legal, regulatory or ethical violations by such person; and provided, further, that the failure of any indemnified
party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent
that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation.
It is understood and agreed that the indemnifying party shall not, in connection with any Claim in the same jurisdiction, be liable
for fees or expenses of more than one separate firm of attorneys at any time for all such Investor Indemnified Persons. No indemnifying
party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that
(i) does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release
from all liability in respect of such claim or litigation or (ii) that includes the granting of any equitable relief or the admission
by the indemnified party of its officers, directors, managers, partners or Affiliates of any legal, regulatory or ethical violations.

 

    	25

    	 

    

 

8.4.         Remedies. Investors
shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which Investors have been
granted at any time under any other agreement or contract and all of the rights which Investors has under any law. The Company
recognizes that in the event that it fails to perform, observe or discharge any or all of its obligations under the Transaction
Documents, any remedy at law may prove to be inadequate relief to the Investors. The Company therefore agrees that the Investors
shall be entitled to seek specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief
from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a
bond or other security.

 

9.         Miscellaneous.

 

9.1.         Successors and Assigns.
After the Closing, each Investor may assign its rights and obligations hereunder, in connection with any private sale or transfer
of Preferred Shares or Warrants in accordance with the terms hereof, as long as, as a condition precedent to such transfer, the
transferee executes an acknowledgment agreeing to be bound by the applicable provisions of this Agreement, in which case the term
“Investor” shall be deemed to refer to such transferee as though such transferee were an original signatory hereto.
The Company may not assign its rights or obligations under this Agreement without the prior written consent of the Investors. The
provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns
of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.

 

9.2.         Independent Nature
of Investors Obligations and Rights. The obligations of the Investors under the Transaction Documents are several and not joint,
and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction
Document Nothing contained herein or in any other Transaction Document, and no action taken by an Investor pursuant hereto or thereto,
shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership,
an association, a joint venture or any other kind of group or entity, or create a presumption that the Investors are in any way
acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by the Transaction
Documents or any matters, and the Company acknowledges that the Investors are not acting in concert or as a group, and the Company
shall not assert any such claim, with respect to such obligations or the transactions contemplated by the Transaction Documents.
The decision of each of the Investors to purchase securities pursuant to the Transaction Documents has been made by such Investors
independently of any other Investors.

 

9.3.         Counterparts; Faxes.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed an original.

 

    	26

    	 

    

 

9.4.         Titles and Subtitles.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

9.5.         Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively
given as hereinafter described: (i) if given by personal delivery, then such notice shall be deemed given upon such delivery; (ii)
if given by telecopier, then such notice shall be deemed given one Business Day after transmission with written confirmation of
successful transmittal; (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such
notice by the recipient or (B) three (3) days after such notice is deposited in first class mail, postage prepaid; and (iv) if
given by overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier with written
confirmation of successful delivery. All notices shall be addressed to the party to be notified at the address as follows, or at
such other address as such party may designate by ten (10) days’ advance written notice to the other party:

 

If to the Company:

 

Adamis Pharmaceuticals Corporation

11682 El Camino Real, Suite 300

San Diego, CA 92130 

Attention: Dennis J. Carlo, Ph.D. 

Fax: (866) 893-3622

 

With a copy to:

 

Weintraub Tobin Chediak Coleman Grodin
Law Corporation

400 Capitol Mall, 11th Floor

Sacramento, CA 95814 

Attention: C. Kevin Kelso, Esq. 

Fax: (916) 446-1611

 

If to the Investor:

 

to the address set forth on
the signature page hereto.

 

With a copy to:

 

Ropes & Gray LLP 

Prudential Tower

800 Boylston Street

Boston, MA 02199 

Attention: Joel F. Freedman, Esq. 

Fax: (617) 235-0375

 

    	27

    	 

    

 

9.6.         Expenses.
The parties hereto shall pay their own costs and expenses in connection herewith, except that the Company shall pay the
reasonable fees and expenses of Ropes & Gray LLP, counsel to the Investors, in connection with the transactions
contemplated by this Agreement and the other Transaction Documents (including review of the Registration Statement
contemplated by the Registration Rights Agreement). An estimate of the fees and expenses of Ropes & Gray, LLP may be paid
by check delivered or wire transfer to Ropes & Gray, LLP at the Closing by any Investor, the amount of such check or wire
transfer being deducted from the aggregate amount to be delivered by such entity at the Closing for the Securities to be
purchased by it hereunder. In the event that legal proceedings are commenced by any party to this Agreement against another
party to this Agreement in connection with this Agreement or the other Transaction Documents, the party that does not prevail
in such proceedings shall pay the reasonable attorneys’ fees and other reasonable out-of-pocket costs and expenses
incurred by the prevailing party in such proceedings.

 

9.7.         Amendments and Waivers.
Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in
a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Required
Investors. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Securities
purchased under this Agreement at the time outstanding, each future holder of all such Securities, and the Company.

 

9.8.         Publicity. Except
as set forth below, no initial public release or announcement concerning the transactions contemplated hereby shall be issued by
the Company or an Investor without the prior consent of the Company (in the case of a release or announcement by the Investor)
or the Required Investors (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld),
except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange
or securities market, in which case the Company or an Investor, as the case may be, shall allow the Required Investors or the Company,
as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement
in advance of such issuance. No later than the fourth trading day following the execution and delivery of this Agreement, the Company
will file a Current Report on Form 8-K describing the transactions contemplated by this Agreement.

 

9.9.         Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable
in any respect.

 

9.10.       Entire Agreement.
This Agreement, including the Exhibits and the Schedules, and the other Transaction Documents constitute the entire agreement among
the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
both oral and written, between the parties with respect to the subject matter hereof and thereof.

 

9.11.       Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other
actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of
the agreements herein contained.

 

    	28

    	 

    

 

9.12.       Governing Law; Consent
to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the internal
laws of the State of New York, without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits
to the exclusive jurisdiction of the federal and state courts located in New York for the purpose of any suit, action, proceeding
or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection
with any such suit, action or proceeding may be served on each party hereto by the same methods as are specified for the giving
of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such
suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the
laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit,
action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES HERETO WAIVES
ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED
SPECIFICALLY AS TO THIS WAIVER.

 

[SIGNATURE PAGE FOLLOWS]

 

    	29

    	 

    

 

IN WITNESS WHEREOF, the
parties have executed this Purchase Agreement or caused their duly authorized officers to execute this Agreement as of the date
first above written.

 

		Company: 

ADAMIS PHARMACEUTICALS CORPORATION  
	 	 	 
	 	By:	/s/ Dennis J. Carlo
	 	 	Name:Dennis J. Carlo, Ph.D.
	 	 	Title:Chief Executive Officer

  

[Investor Signature Page Follows]

 

    	 

    	 

    

 

Investor Signature Page

 

 

	 	Sio Partners LP

By: Sio GP, LLC, its general partner

	 	 
	 	By:	/s/ Michael Castor
	 	Name:

        Title:
	    Michael Castor
  Managing Member

 

 

	 	Sio Partners QP LP

By: Sio GP, LLC, its general partner

	 	 
	 	By:	/s/ Michael Castor
	 	Name:

        Title:
	    Michael Castor
  Managing Member

 

 

 

	 	Sio Partners Offshore, Ltd.

	 	 
	 	By:	/s/ Michael Castor
	 	Name:

        Title:
	    Michael Castor
  Director

 

ADDRESS FOR DELIVERY:

  

_________________________________

 

Attention: _________________________

 

Tel: ______________________________

 

Fax: ______________________________

 

E-mail: ___________________________

 

	Aggregate Purchase Price: 	$______________	 
	 	 	 
	Units Purchased:	_______________Adamis Pharmaceuticals Corporation 8-K

Exhibit
10.2 

 

Execution Version

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights Agreement
(the “Agreement”) is dated as of August 19, 2014 (the “Agreement Date”) and is entered
into by and among Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the “Investors”
named in that certain Purchase Agreement dated the date hereof and entered into by and between the Company and each of the Investors
(the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the
Purchase Agreement unless otherwise defined herein.

 

The parties hereby agree as
follows:

 

		1.	Certain Definitions.

 

As used in this Agreement,
the following terms shall have the following meanings:

 

“Investors”
means the Investors identified in the Purchase Agreement and any Affiliate or permitted transferee of any Investor who is a subsequent
holder of any Registrable Securities.

 

“Prospectus”
means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by
all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the 1933 Act.

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness
of such Registration Statement or document.

 

“Registrable Securities”
means, collectively, the (i) the Shares, (ii) the Warrant Shares, and (iii) any other securities issued or issuable with respect
to or in exchange for Registrable Securities, whether by merger, charter amendment or otherwise; provided, that, a security shall
cease to be a Registrable Security upon (A) sale to the public pursuant to a Registration Statement or Rule 144 under the 1933
Act, or (B) such security becoming eligible for sale without volume restrictions by the applicable Investor pursuant to Rule 144
(and, with respect to Warrant Shares, giving effect to and assuming a net exercise of the Warrant by the Investor).

 

“Registration Deadline”
means the one hundred twentieth (120th) calendar day following the Closing Date.

 

“Registration Statement”
means any registration statement of the Company filed under the 1933 Act that covers the resale of any of the Registrable Securities
pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement, including post-effective
amendments, all exhibits and all material incorporated by reference in such Registration Statement.

 

    	 

    	 

    

 

“Required Investors”
means the Investors beneficially owning a majority of the Registrable Securities (without taking into account any limitations on
conversion or exercise).

 

“SEC” or
the “Commission” means the U.S. Securities and Exchange Commission.

 

“Shares”
means the shares of Common Stock that are issued or issuable upon conversion of the shares of the Company’s Series A Convertible
Preferred Stock (“Series A Preferred”) that were issued pursuant to the Purchase Agreement (without taking into
account any limitations on conversion).

 

“Warrants”
means the Common Stock purchase warrants issued to the Investors pursuant to the Purchase Agreement.

 

“Warrant Shares”
means the shares of Common Stock issued or issuable upon exercise of the Warrants (without taking into account any limitations
on conversion).

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

		2.	Registration.

 

(a)         Registration Statements.

 

(i)         Filing of Registration
Statement. As soon as reasonably practicable following the Agreement Date but no later than sixty (60) days after the Agreement
Date (the “Initial Filing Deadline”), the Company shall prepare and file with the SEC one Registration Statement
on Form S-3 (or, if Form S-3 is not then available to the Company, on such form of registration statement as is then available
to effect a registration for resale of the Registrable Securities), covering the resale of all of the Registrable Securities, and
shall use its best efforts to cause such Registration Statement to be declared effective as promptly as reasonably practicable
thereafter. Subject to any SEC comments, such Registration Statement shall include the plan of distribution attached hereto as
Exhibit A (or such other plan reasonably requested by the Required Investors). Such Registration Statement also shall cover,
to the extent allowable under the 1933 Act and the rules promulgated thereunder (including Rule 416), such indeterminate number
of additional shares of Common Stock as may become issuable due to an increase in the number of Shares or Warrant Shares resulting
from changes in the conversion rate of the Series A Preferred, or the number of shares issuable upon exercise of the Warrants.
Such Registration Statement may include any shares of Common Stock or other securities for the account of any other holder with
registration rights pursuant to written agreements entered into with the Company before the date of this Agreement (or such shares
may be registered on separate registration statements filed before or after the Registration Statement is filed), but shall not
include any other shares of Common Stock or other securities without the prior written consent of the Required Investors. Except
as contemplated by the preceding sentence or pursuant to registration statements filed and declared effective by the SEC before
the Agreement Date, the Company shall not register additional shares of Common Stock until the Registration Statement is declared
effective or, if earlier, until the Registrable Securities no longer constitute Registrable Securities. The Registration Statement
(and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance
with

 

    	2

    	 

    

 

Section 3(c) to the Investors and their counsel prior to its filing
or other submission. If a Registration Statement covering the Registrable Securities as provided above is not filed with the SEC
on or prior to the Initial Filing Deadline the Company will make pro rata payments to each Investor, as liquidated damages and
not as a penalty, in an amount equal to one percent (1.0%) of the aggregate purchase price of the Warrants and Series A Preferred
purchased by such Investor pursuant to the Purchase Agreement for each 30-day period or pro rata for any portion thereof following
the Initial Filing Deadline for which no Registration Statement is filed with respect to the Registrable Securities, until such
time as the Registrable Securities (giving effect to and assuming a net exercise of the Warrant by the Investor) may be sold without
volume limitations pursuant to Rule 144. Any such payment shall be in addition to any other remedies available to the Investor
at law or in equity, whether pursuant to the terms hereof, the Purchase Agreement, the Certificate of Designation, or otherwise.
Such payments shall be made to each Investor in cash no later than three (3) Business Days after the end of each 30-day period.

 

(b)         Expenses. The
Company will pay all expenses associated with effecting the registration of the Registrable Securities, including filing and printing
fees, the Company’s counsel and accounting fees and expenses, costs associated with clearing the Registrable Securities for
sale under applicable state securities laws, listing fees, and reasonable fees and expenses of one counsel to the Investors, but
excluding discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals
with respect to the Registrable Securities being sold.

 

(c)         Effectiveness.

 

(i)         The Company shall use
best efforts to have the Registration Statement declared effective as soon as reasonably practicable after filing, but in no event
later than the Registration Deadline. The Company shall respond promptly to any and all comments made by the staff of the Commission
on the Registration Statement, and shall submit to the Commission, with two (2) Business Days after the Company learns that no
review of the Registration Statement will be made by the staff of the Commission or that the staff of the Commission has no further
comments on the Registration Statement, as the case may be, a request for acceleration of the effectiveness of the Registration
Statement to a time and date not later than two (2) Business Days after the submission of such request. The Company shall notify
the Investors by facsimile or e-mail as promptly as reasonably practicable, and in any event, within twenty-four (24) hours, after
the Registration Statement is declared effective and shall simultaneously provide or make available to the Investors copies of
any related Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. If, subject
to Section 2(d) hereof, (A) a Registration Statement covering the Registrable Securities is not declared effective by the SEC prior
to the earlier of (i) five (5) Business Days after the SEC shall have informed the Company that no review of the Registration Statement
will be made or that the SEC has no further comments on the Registration Statement or (ii) the 60th day after the Initial
Filing Deadline (the 90th day if the SEC reviews the Registration Statement), or (B)
after the Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration Statement
for any reason (including without limitation by reason of a stop order, or the Company’s failure to update the Registration
Statement), but excluding the inability of any Investor to sell the Registrable Securities covered thereby solely due to market
conditions, then the Company will make pro rata payments to each Investor, as liquidated

 

    	3

    	 

    

 

damages and not as a penalty, in an amount equal to 1.0% of the
aggregate amount invested by such Investor for each 30-day period or pro rata for any portion thereof following the date by which
such Registration Statement should have been effective (the “Blackout Period”), until such time as the Registrable
Securities (giving effect to and assuming a net exercise of the Warrant by the Investor) may be sold without volume limitations
pursuant to Rule 144. Any such payment shall be in addition to any other remedies available to the Investor at law or in equity,
whether pursuant to the terms hereof, the Purchase Agreement, the Certificate of Designation, or otherwise. The amounts payable
as liquidated damages pursuant to this paragraph shall be paid monthly within three (3) Business Days of the last day of each month
following the commencement of the Blackout Period until the termination of the Blackout Period. Such payments shall be made to
each Investor in cash.

 

(ii)        For not more than
sixty (60) days (which need not be consecutive days) in any twelve (12) month period, the Company may suspend the use of any Prospectus
included in any Registration Statement contemplated by this Section in the event that the Company determines in good faith that
such suspension is necessary to (A) delay the disclosure of material non-public information concerning the Company, the disclosure
of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B) amend or supplement
the affected Registration Statement or the related Prospectus so that such Registration Statement or Prospectus shall not include
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in the case of the Prospectus in light of the circumstances under which they were made, not misleading (an
“Allowed Delay”); provided, that the Company shall promptly (a) notify each Investor in writing of the commencement
of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any material non-public
information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under the Registration Statement
until the end of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable.
Notwithstanding the provisions of this Section, if an Allowed Delay is not in connection with the review by the SEC of a Registration
Statement or the financial statements contained therein, such Allowed Delay shall not be for a period exceeding twenty (20) consecutive
days. Although an Allowed Delay would not be a breach of this Agreement, liquidated damages would accrue during such Allowed Delay
pursuant to Section 2(c)(i).

 

(d)         Rule 415; Cutback
If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a Registration Statement
is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933 Act or requires any
Investor to be named as an “underwriter,” the Company shall use its reasonable best efforts to persuade the SEC that
the offering contemplated by the Registration Statement is a valid secondary offering and not an offering “by or on behalf
of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter.” The Investors shall
have the right to participate or have their counsel participate in any meetings or discussions with the SEC regarding the SEC’s
position and to comment or have their counsel comment on any written submission made to the SEC with respect thereto. No such written
submission shall be made to the SEC to which the Investors’ counsel reasonably objects. In the event that, despite the Company’s
best efforts and compliance with the terms of this Section 2(d), the SEC refuses to alter its position, the Company shall (i) remove
from the Registration Statement such portion of

 

    	4

    	 

    

 

the Registrable Securities (the “Cut Back Shares”)
and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC
may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”).
Any cut-back imposed on the Investors pursuant to this Section 2(d) shall be allocated among the Investors on a pro rata basis
and shall be applied first to any Warrant Shares covered by such Registration Statement, unless the SEC Restrictions otherwise
require or provide or the Investors otherwise agree. Such required cut-back would not be considered a breach of this Agreement
unless continuing past the 60th day (or the 90th day if the SEC reviews the registration statement) after
such date as the Company is permitted to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions
(such date, the “Restriction Termination Date” of such Cut Back Shares), provided that liquidating damages would
accrue as a result as provided in Section 2(c)(i).

 

3.         Company Obligations.
The Company will use best efforts to effect the registration of the Registrable Securities in accordance with the terms hereof,
and pursuant thereto the Company will, as expeditiously as possible:

 

(a)         use best efforts to cause
such Registration Statement to become effective and to remain continuously effective (other than during an Allowed Delay) for a
period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement
as amended from time to time, have been sold, and (iii) the date on which all Registrable Securities covered by such Registration
Statement may be sold without volume restriction pursuant to Rule 144 (giving effect to and assuming a net exercise of the Warrant
by the Investor) (the “Effectiveness Period”) and advise the Investors in writing when the Effectiveness Period
has expired;

 

(b)         prepare and file with
the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be necessary to keep
the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933 Act and the 1934
Act with respect to the distribution of all of the Registrable Securities covered thereby;

 

(c)         provide copies to and
permit counsel designated by the Investors to review each Registration Statement and all amendments and supplements thereto no
fewer than two (2) days prior to their filing with the SEC and not file any document to which such counsel reasonably objects,
provided that the Company is notified of such objection, including the substance of such objection, in writing no later than three
Business Days after such counsel has been so furnished copies of such documents;

 

(d)         furnish
or otherwise make available (including via EDGAR) to the Investors and their legal counsel (i) promptly after the same is
prepared and publicly distributed, filed with the SEC, or received by the Company (but not later than two (2) Business Days
after the filing date, receipt date or sending date, as the case may be) one (1) copy of any Registration Statement and any
amendment thereto, each preliminary prospectus and Prospectus and each amendment or supplement thereto, and each letter
written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or
the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any thereof which
contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a
Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as each
Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor
that are covered by the related Registration Statement;

 

    	5

    	 

    

 

(e)         use best efforts to (i)
prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal
of any such order at the earliest possible moment and to notify the Investors of the issuance of such order and the resolution
thereof;

 

(f)         use best efforts to register
or qualify (unless an exemption from the registration or qualification exists) or cooperate with the Investors and their counsel
in connection with the registration or qualification of such Registrable Securities for offer and sale under the securities or
blue sky laws of such domestic jurisdictions as are reasonably requested by the Investors and do any and all other commercially
reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities
covered by the Registration Statement; provided, however, that the Company shall not be
required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not
otherwise be required to qualify but for this Section 3(f), (ii) subject itself to general taxation in any jurisdiction where it
would not otherwise be so subject but for this Section 3(f), or (iii) file a general consent to service of process in any such
jurisdiction;

 

(g)         use
best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on each securities
exchange, interdealer quotation system or other market on which similar securities issued by the Company are then listed;

 

(h)         immediately notify the
Investors, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening of any event as
a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and,
subject to Section 2(c)(ii) hereof promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment
of such Prospectus as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances then existing;

 

(i)         otherwise use best efforts
to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934 Act, including, without limitation,
Rule 172 under the 1933 Act, file any final Prospectus, including any supplement or amendment thereof, with the SEC pursuant to
Rule 424 under the 1933 Act, promptly inform the Investors in writing if, at any time during the Effectiveness Period, the Company
does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investors are required to deliver a Prospectus
in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate
the registration of the Registrable Securities hereunder; and

 

    	6

    	 

    

 

(j)         with a view to making available to the Investors the benefits
of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell
shares of Common Stock to the public without registration, the Company covenants and agrees to: (i) make and keep public information
available, as those terms are understood and defined in Rule 144, until the earlier of (A) such date as all of the Registrable
Securities may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B)
such date as all of the Registrable Securities shall have been resold; (ii) file with the SEC in a timely manner all reports and
other documents required of the Company under the 1934 Act; and (iii) furnish to each Investor upon request (including via EDGAR),
as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the
reporting requirements of the 1934 Act, (B) a copy (or a link to a website containing the same) of the Company’s most recent
Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order
to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without
registration under Rule 144.

 

4.         Due Diligence Review;
Information. The Company shall make available, during normal business hours, for inspection and review by the Investors, advisors
to and representatives of the Investors (who may or may not be affiliated with the Investors and who are reasonably acceptable
to the Company), all SEC Filings (as defined in the Purchase Agreement) and other filings with the SEC, and all other corporate
documents and properties of the Company as may be reasonably necessary for the purpose of such review, for the sole purpose of
enabling the Investors and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct
initial and ongoing due diligence with respect to the accuracy of such Registration Statement.

 

 5.         Obligations of the Investors.

 

(a)         Each Investor shall furnish
in writing to the Company such information regarding itself, the Registrable Securities and Company securities held by it and the
intended method of disposition of the Registrable Securities held by it, as shall be required to effect the registration of such
Registrable Securities, to respond to requests by the SEC, FINRA or any state securities commission or as may be required to be
disclosed by applicable securities laws and shall execute such documents in connection with such registration as the Company may
reasonably request. At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement, the
Company shall notify each Investor of the information the Company requires from such Investor if such Investor elects to have any
of the Registrable Securities included in the Registration Statement.

 

(b)         Each Investor agrees
that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to Section 2(c)(ii)
or (ii) the happening of an event pursuant to Section 3(h) hereof, such Investor will use its commercially reasonable efforts to
promptly discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities,
until the Investor is advised by the Company that such dispositions may again be made. The Company may provide appropriate stop
orders to enforce the provisions of this paragraph.

 

    	7

    	 

    

 

(c)         The Company shall have no obligation to make liquidated damages
payments under this Agreement to any Investor as a result of delays caused by its breach of these obligations.

 

 6.         Indemnification.

 

(a)         Indemnification by
the Company. To the extent permitted by law, the Company will indemnify and hold harmless each Investor and its officers, directors,
members, employees and agents, successors and assigns, and each other person, if any, who controls, or is alleged to control, such
Investor within the meaning of the 1933 Act, against any losses, claims, damages or liabilities, joint or several, to which they
may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of
any material fact contained in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or
supplement thereof; (ii) any blue sky application or other document executed by the Company specifically for that purpose or based
upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the
Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue
Sky Application”); (iii) the omission or alleged omission to state in a Blue Sky Application a material fact required
to be stated therein or necessary to make the statements therein not misleading; (iv) any violation by the Company or its agents
of any rule or regulation promulgated under the 1933 Act applicable to the Company or its agents and relating to action or inaction
required of the Company in connection with such registration; or (v) any failure to register or qualify the Registrable Securities
included in any such Registration Statement in any state where the Company or its agents has affirmatively undertaken or agreed
in writing that the Company will undertake such registration or qualification on an Investor’s behalf pursuant to an Investor’s
affirmative request under Section 3(f) hereof and will reimburse such Investor, and each such officer, director or member and each
such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any
such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement
or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Investor or
any such controlling person relating to such Investor in writing specifically for use in such Registration Statement or Prospectus.

 

(b)         Indemnification
by the Investors. Each Investor who is named in such Registration Statement as a selling stockholder agrees, severally
but not jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors,
officers, employees, stockholders and each person who controls the Company (within the meaning of the 1933 Act) against any
losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from (i) any untrue statement
of a material fact or any omission of a material fact required to be stated in the Registration Statement or Prospectus or
preliminary Prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, to the
extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by
such Investor to the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or
supplement thereto and (ii) the sale of Registrable Securities in violation of Section 5(c) hereof; provided, however, that
the foregoing indemnity shall not apply to amounts paid in settlement of any loss, claim, damage, liability or expense if
such settlement is effected without the consent of such Investor. In no event shall the liability of an Investor be greater
in amount than the dollar amount of the net proceeds received by such Investor upon the sale of the Registrable Securities
included in the Registration Statement giving rise to such indemnification obligation.

 

    	8

    	 

    

 

(c)         Conduct of Indemnification
Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any
claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim
with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder
shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such
counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, or (b)
the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such
person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest may
exist between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying
party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further,
that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the
defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding
in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified
parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter
into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect of such claim or litigation.

 

(d)         Contribution.
If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party
or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to
the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as
is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant
equitable considerations. Relative fault shall be determined by reference to whether any alleged untrue statement or omission relates
to information provided by the Company or by a holder of Registrable Securities. No person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any person not guilty of such fraudulent
misrepresentation. In no event shall the contribution obligation of a holder of Registrable Securities together with any indemnification
obligations under Section 6(b) above be greater in amount than the dollar amount of the net received by it upon the sale of the
Registrable Securities giving rise to such contribution obligation.

 

    	9

    	 

    

 

(e)         The obligations of the Company and each Investor under this
Section 6 shall survive the conversion of the Series A Preferred Stock and exercise of the Warrants in full, the completion of
any offering or sale of Registrable Securities pursuant to a Registration Statement under this Agreement, or otherwise.

 

 7.         Miscellaneous.

 

(a)         Amendments and Waivers.
This Agreement may be amended only by a writing signed by the Company and the Required Investors. The Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall have obtained the
written consent to such amendment, action or omission to act, of the Required Investors.

 

(b)         Notices. All notices
and other communications provided for or permitted hereunder shall be made as set forth in Section 9.4 of the Purchase Agreement.

 

(c)         Assignments and Transfers
by Investors. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investors and their respective
successors and assigns. An Investor may transfer or assign, in whole or from time to time in part, to one or more persons its rights
hereunder in connection with the transfer of Registrable Securities by such Investor to such person, provided that such Investor
provides written notice of assignment to the Company promptly after such assignment is effected.

 

(d)         Assignments and Transfers
by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise) without the prior
written consent of the Required Investors, provided, however, that in the event that the Company is a party to a merger, consolidation,
share exchange or similar business combination transaction, or a transaction involving the transfer or other disposition of all
or substantially all of the Company’s assets to another corporation or entity, or similar transaction, the Company may assign
its rights and delegate its duties hereunder to any surviving or successor corporation without the prior written consent of the
Required Investors, after notice duly given by the Company to each Investor. In any such transaction in which the Common Stock
is converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall,
by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company”
shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities
received by the Investors in connection with such transaction unless such securities are otherwise freely tradable by the Investors
after giving effect to such transaction.

 

(e)         Benefits of the Agreement.
The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors
and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement.

 

    	10

    	 

    

 

(f)         Counterparts;
Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall
be deemed an original.

 

(g)         Titles and Subtitles.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

(h)         Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable
in any respect.

 

(i)         Further Assurances.
The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably
be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.

 

(j)         Entire Agreement.
This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive
statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. This Agreement
supersedes all prior agreements and understandings between the parties with respect to such subject matter.

 

(k)         Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties
hereto irrevocably submits to the exclusive jurisdiction of the courts of the federal and state courts located in New York
for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions
contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party
hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the
parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the
laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit,
action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought
in any such court has been brought in an inconvenient forum.  TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH OF THE PARTIES
HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

    	11

    	 

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

 

	The Company:	ADAMIS PHARMACEUTICALS CORPORATION
	 	 	 
	 	By:	/s/ Dennis J. Carlo
	 	Name:        Dennis J. Carlo, Ph.D.
	 	Title:          Chief Executive Officer

  

[Investor Signature Page Immediately Follows]

 

    	 

    	 

    

 

Counterpart
Signature Page

 

 

	FOR ENTITY INVESTORS:  	 	FOR INDIVIDUAL INVESTORS:
	 	 	 
	Sio Partners LP

By: Sio GP, LLC, its general partner

	 	Signature:________________________

        Name:___________________________

	 	 	
	By:	/s/ Michael Castor	 	
	Name:

        Title:
	    Michael Castor
  Managing Member	 	 

 

 

	Sio Partners QP LP

By: Sio GP, LLC, its general partner

	 
	 	 
	By:	/s/ Michael Castor	 
	Name:

        Title:
	    Michael Castor
  Managing Member	 

 

 

 

	Sio Partners Offshore, Ltd.

	 
	 	 
	By:	/s/ Michael Castor	 
	Name:

        Title:
	    Michael Castor
  Director	 

 

 

 

    	 

    	 

    

 

Exhibit A

 

Plan of Distribution

 

The selling stockholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests
in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership
distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common
stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling stockholders
may use any one or more of the following methods when disposing of shares or interests therein:

 

		–	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		–	block trades in which the broker-dealer will attempt to sell the shares as agent, but may position
and resell a portion of the block as principal to facilitate the transaction;

 

		–	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		–	an exchange distribution in accordance with the rules of the applicable exchange;

 

		–	privately negotiated transactions;

 

		–	short sales effected after the date the registration statement of which this Prospectus is a part
is declared effective by the SEC;

 

		–	through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;

 

		–	broker-dealers may agree with the selling stockholders to sell a specified number of such shares
at a stipulated price per share;

 

		–	a combination of any such methods of sale; and

 

		–	any other method permitted by applicable law.

 

    	 

    	 

    

 

The selling
stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned
by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and
sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under
Rule 424(b)(3) or other applicable provision of the 1933 Act amending the list of selling stockholders to include the
pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders
also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other
successors in interest will be the selling beneficial owners for purposes of this prospectus.

 

In connection with the
sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The aggregate proceeds
to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less
discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.
We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will
receive the exercise price of the warrants.

 

The selling stockholders
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the 1933 Act, provided
that they meet the criteria and conform to the requirements of that rule.

 

The selling stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters”
within the meaning of Section 2(11) of the 1933 Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the 1933 Act. Selling stockholders who are “underwriters”
within the meaning of Section 2(11) of the 1933 Act will be subject to the prospectus delivery requirements of the 1933 Act.

 

To the extent required,
the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.

 

In order to comply
with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been
registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with.

 

    	 

    	 

    

 

We have advised the selling
stockholders that the anti-manipulation rules of Regulation M under the 1934 Act may apply to sales of shares in the market and
to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies of
this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose
of satisfying the prospectus delivery requirements of the 1933 Act. The selling stockholders may indemnify any broker-dealer that
participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the 1933 Act.

 

We have agreed to indemnify
the selling stockholders against liabilities, including liabilities under the 1933 Act and state securities laws, relating to the
registration of the shares offered by this prospectus.

 

We have agreed with the
selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier
of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration
statement or (2) the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the 1933 Act.

 

    	 

    	 

    

 

Exhibit C

 

Selling Securityholder Notice and Questionnaire

 

The undersigned beneficial
owner of common stock (the “Registrable Securities”) of Adamis Pharmaceuticals Corporation, a Delaware corporation
(the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange
Commission (the “Commission”) a registration statement (the “Registration Statement”) for
the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”),
of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration Rights
Agreement”) of which this document is an exhibit. A copy of the Registration Rights Agreement is available from the Company
upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed
thereto in the Registration Rights Agreement.

 

Certain legal consequences
arise from being named as a selling securityholder in the Registration Statement and the related prospectus. Accordingly, holders
and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling securityholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned holder
(the “Selling Securityholder”) of Registrable Securities hereby elects to include the Registrable Securities
owned by it and listed below in Item 3 (unless otherwise specified under such Item 3) in the Registration Statement. The undersigned,
by signing and returning this Notice and Questionnaire, understands that it will be bound by the terms and conditions of this Notice
and Questionnaire and the Registration Rights Agreement.

 

    	 

    	 

    

 

The undersigned hereby provides the following
information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

	1.	Name.
	 	 	 	 
	 	(a)	Full Legal Name of Selling Securityholder
	 	 	 	 
	 	 	 
	 	 	 	 
	 	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities listed in Item 3 below are held:
	 	 	 	 
	 	 	 
	 	 	 	 
	 	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by the questionnaire):
	 	 	 	 
	 	 	 
	 	 	 	 
	2.	Address for Notices to Selling Securityholder:

	 	 	 	 
	 	 	 	 
	 	 	 	 
	Telephone:	 
	Fax:	 
	Contact Person:	 

 

	3.	Beneficial Ownership of Registrable Securities:
	 	 	 
	 	(a)	Type and Number of Registrable
Securities beneficially owned:
	 	 	 
	 	 	 
	 	 	 

 

    	 

    	 

    

 

	4.	Broker-Dealer Status:
	 	 	 
	 	(a)	Are you
a broker-dealer?
	 	 	 
	 	 	Yes ☐           No ☐
	 	 	 
	 	(b)	If
“yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services
to the Company?
	 	 	 
	 	 	Yes ☐           No ☐
	 	 	 
	 	Note:	If
no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
	 	 	 
	 	(c)	Are you
an affiliate of a broker-dealer?
	 	 	 
	 	 	Yes ☐           No ☐
	 	 	 
	 	(d)	If you
are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or
indirectly, with any person to distribute the Registrable Securities?
	 	 	 
	 	 	Yes ☐           No ☐
	 	 	 
	 	Note:	If
no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
	 	 	 
	5.	Beneficial Ownership of Other Securities of the Company Owned by the
              Selling Securityholder.
	 	 
	 	Except as set forth below in this
Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable
pursuant to the Purchase Agreement and listed above in Item 3.
	 	 
	 	(a)	Type
and Amount of other securities beneficially owned by the Selling Securityholder:
	 	 	 
	 	 	 

  

    	 

    	 

    

 

	6.	Relationships with the Company:
	 	 	 
	 	Except as set forth below,
neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of
the equity securities of the undersigned) has held any position or office or has had any other material relationship with the
Company (or its predecessors or affiliates) during the past three years.
	 	 	 
	 	State any exceptions here:
	 	 	 
	 	 	 

  

The undersigned agrees
to promptly notify the Company of any inaccuracies or changes in the information provided herein (i) that may occur subsequent
to the date hereof until the effective date of the Registration Statement (other than changes in ownership) and (ii) at any time
while the Registration Statement remains effective if requested by the Company in connection with the filing of a prospectus supplement
or a post-effective amendment. All notices hereunder shall be made in writing at the address set forth below.

 

By signing below, the undersigned
consents to the disclosure of the information contained herein in its answers to Items 1 through 6 and the inclusion of such information
in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands
that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement
and the related prospectus.

 

    	 

    	 

    

 

IN WITNESS WHEREOF the
undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or
by its duly authorized agent.

 

	Dated: ________________	Selling Securityholder: ___________________
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

  

PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE,
AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:

 

[_____________]

_________________

______________

Attention: Chief Financial Officer 

Fax No.: (___) ___-____

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]